Ulixertinib by BioMed Valley Discoveries for Neurofibromatoses Type I (Von Recklinghausen’s Disease): Likelihood of Approval

Ulixertinib is under clinical development by BioMed Valley Discoveries and currently in Phase I for Neurofibromatoses Type I (Von Recklinghausen’s Disease).

AI-based MRI tools show promise in multiple sclerosis diagnosis

A groundbreaking study in NPJ Digital Medicine demonstrates the superior accuracy of AI-based imaging in diagnosing and monitoring multiple sclerosis.

October 24, 2023

Meta Title: AstraZeneca Plc Patent: Improved AAV Vector Production with Specific Plasmid Sequence

Share this article According to GlobalData’s company profile on AstraZeneca, Personalized cancer vaccines was a key innovation area identified from patents. AstraZeneca‘s grant share as

March 12, 2024

Opinion | Is West Nile Virus on Your Radar? It Should Be.

Panosian Dunavan is an infectious diseases expert. Not long ago, a colleague shared a tragic story about a man with a failing heart. The good

July 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.